Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- TLYS +18.5%, CAL +10%, AI +0.8%, BKE +0.5% (May comps)
Other news:
- VSTM +5.2% (FDA grants Fast Track Designation for VS-7375)
- RCEL +4.7% (stockholders approved of the issuance of equity securities)
- SNY +3.4% (launches 2026 employee stock purchase plan)
- GLBE +3.1% (authorization of $500 mln share repurchase program)
- ZSQR +2.6% (entered into a $50 mln committed equity forward purchase agreement with LucentHash / Data Part Capital, a trading name of Translucent Matter)
- PHAR +2.1% (receives FDA acceptance for pediatric Joenja filing)
- COST +2% (May same store comps)
- MCHP +2% (received approval from the U.S. Department of Commerce's Bureau of Industry and Security for an export license authorizing the use of advanced technology under Export Control Classification Number 3E001 and related high-performance hardware under ECCN?3A001.a.7.b.)
- GNK +1.9% (issues letter to shareholders)
- NVS +1.7% (IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years)
- GHRS +1.6% (reports publication of Phase 2a Postpartum Depression Results)
- ODC +1.5% (increases dividend; also authorizes 500,000 share repurchase program)
- IPI +1.2% (increases share repurchase authorization to $50 mln from $35 mln)
- TV +1.2% (issued zero-coupon mandatory convertible debentures into shares in the amount of $6,917,800,007.42 Mexican pesos)
- EL +1.1% (increases expected charge related to restructuring program)
- ADSK +1.1% (collaboration with Amazon Web Services)
- ZG +1% (authorizes additional $1.25 bln in repurchases; also amends repurchase program to limit any shareholder to 45% voting power)
- BIIB +1% (Biogen and UCB present additional Phase 3 lupus data for dapirolizumab pegol)